Breaking News
November 17, 2018 - new horizon in dental, oral and craniofacial research
November 17, 2018 - How does poor air quality affect your health?
November 17, 2018 - New device can regulate children’s blood glucose more like natural pancreas
November 17, 2018 - Game-Changers in Western Blotting and Protein Analysis
November 17, 2018 - FDA announces new actions to limit sale of e-cigarettes to youth
November 17, 2018 - Warmer winter temperatures related to higher crime rates
November 17, 2018 - MCO places increasing emphasis on helping people find and access healthy food
November 17, 2018 - Group of students aim to improve malaria diagnosis using old smartphones
November 17, 2018 - Transplantation of feces may protect preterm children from deadly bowel disease
November 17, 2018 - Researchers explore whether low-gluten diets can be recommended for people without allergies
November 17, 2018 - New and better marker for assessing patients after cardiac arrest
November 17, 2018 - For 7-year-old with failing bone marrow, a life-saving transplant | News Center
November 17, 2018 - New first-line treatment for peripheral T-cell lymphoma approved by FDA
November 17, 2018 - Artificial intelligence could be valuable tool to help young victims disclose traumatic testimony
November 17, 2018 - Breakthrough in the treatment of Restless Legs Syndrome
November 16, 2018 - FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
November 16, 2018 - Eagle Books | Native Diabetes Wellness Program
November 16, 2018 - Patients with common heart failure more likely to have lethal heart rhythms
November 16, 2018 - How AI could help veterinarians code their notes | News Center
November 16, 2018 - Bias-based bullying does more harm to students than generalized bullying
November 16, 2018 - Researchers find first direct evidence that cerebellum plays role in cognitive functions
November 16, 2018 - Non-coding genetic variant plays key role in endothelial function and disease incidence
November 16, 2018 - EMA recommends first all-oral treatment to tackle deadly sleeping sickness
November 16, 2018 - Drug used to treat dizziness may slow down growth of triple-negative breast cancer
November 16, 2018 - AHA: Icosapent Ethyl Cuts CV Risk From Elevated Triglycerides
November 16, 2018 - ‘Orphan’ RNAs make cancer deadlier, but potentially easier to diagnose
November 16, 2018 - Air Cube touches down at hospital | News Center
November 16, 2018 - CRISPR-based tool shown to enhance cell-based immunotherapy
November 16, 2018 - Mechanisms that govern HIV latency differ in the gut and blood, finds study
November 16, 2018 - Researchers unravel mystery of NPM1 protein in acute myeloid leukemia
November 16, 2018 - High school students less likely to select milk, fruit for lunch when fruit juice is available
November 16, 2018 - Football coaches with great emotional competence are more successful
November 16, 2018 - Researchers awarded $10 million grant to address root causes of asthma in Puerto Rico
November 16, 2018 - Health Tip: Manage Morning Sickness
November 16, 2018 - Infant gut microbes altered by mother’s obesity may increase risk for future disease
November 16, 2018 - Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study
November 16, 2018 - ACC Latin America Conference brings experts to discuss latest cardiovascular science
November 16, 2018 - Pooled analysis of Intersect ENT’s steroid releasing implants in patients after frontal sinus surgery to be published
November 16, 2018 - Expectations about pain intensity can become self-fulfilling prophecies
November 16, 2018 - NIH awards $3.4 million to UC researchers to study gastrointestinal lymphatic system
November 16, 2018 - Highlighting Advances in Bioengineering and Analytical Technologies with eBooks
November 16, 2018 - Scientist Dr David Taylor of MR Solutions is a finalist in the BMW i UK Tech Founder Awards
November 16, 2018 - Earlier treatment could help reverse autistic-like behavior in tuberous sclerosis
November 16, 2018 - Sucking your baby’s pacifier could improve their health
November 16, 2018 - Vegetables and salad may include bacteria that are resistant to antibiotics
November 16, 2018 - Autism linked to prolonged connection between brain regions
November 16, 2018 - Endocrine Society chooses four Diabetes Caucus leaders as winners of Diabetes Champion Award
November 16, 2018 - Brain and muscle cells found within kidney organoids
November 16, 2018 - Person’s sex hormones may play key role in trauma survival, finds study
November 16, 2018 - PTEN Genetic Test: MedlinePlus Lab Test Information
November 16, 2018 - Toxic metal pollution linked with development of autism spectrum disorder
November 16, 2018 - Calcified nodules in the retina increase risk for progression to late stages of AMD
November 16, 2018 - ZEISS teams up with arivis AG to offer complete 3D imaging solutions
November 16, 2018 - Georgia State professor receives $1.2 million grant to study how the brain controls eating behavior
November 16, 2018 - Specific bacterial toxins reduce number of cells suppressing immune response
November 16, 2018 - Review by ID physician improves outcomes for outpatient parenteral antimicrobial therapy
November 16, 2018 - Conditions that produce signs similar to arthritis
November 16, 2018 - New artificial intelligence-based method predicts treatment effectiveness
November 16, 2018 - AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM
November 16, 2018 - Surgery remains best treatment for appendicitis, Stanford study finds
November 16, 2018 - Non-surgical fistula creation system Ellipsys becomes key focus of attention at CiDA
November 16, 2018 - Researchers find no link between ‘allergy friendly’ dogs and lower risk of asthma
November 16, 2018 - Researchers elucidate new rules of connectivity of neurons in the neocortex
November 16, 2018 - Treating children with ‘bubble baby disease’
November 16, 2018 - Nexus announces availability of Arsenic Trioxide Injection in the US
November 16, 2018 - Researchers find metabolite shuttle between cells in the liver that may combat tissue fibrosis
November 16, 2018 - AHA: PTSD Common Among Those Who Suffer Tear in the Aorta’s Wall
November 16, 2018 - Many RA patients’ pain related to central nervous system
November 16, 2018 - Changes in Himalayan gut microbiomes linked to diet
November 16, 2018 - Inhibition of prostaglandin E2 enhances ability to combat infectious colitis
November 16, 2018 - Chronic dry eye can slow reading rate and disrupt day to day tasks
November 16, 2018 - Researchers develop new drug molecule that inhibits inflammation
November 16, 2018 - Dementia symptoms peak in winter and spring, study finds
November 16, 2018 - Stanford tobacco researcher weighs in on JUUL
November 16, 2018 - Increasing omega-3 fatty acid intake during pregnancy reduces risk of premature birth, review finds
November 16, 2018 - Researchers find no link between infants waking up at night and later developmental problems
November 16, 2018 - Both parents and children agree about confidential medical services
November 16, 2018 - FDA warns against use of unapproved pain medications with implanted pumps
November 16, 2018 - Precision medicine-based approach to slow or reverse biologic drivers of Alzheimer’s disease
November 16, 2018 - Study provides new insight into norovirus outbreaks, may help guide efforts to develop vaccines
Alzheimer’s Association’s Part the Cloud program funds innovative research on brain cells

Alzheimer’s Association’s Part the Cloud program funds innovative research on brain cells

image_pdfDownload PDFimage_print

Innovative research aimed to possibly rejuvenate brain cells will be explored by six international researchers with the goal of discovering effective drugs for people with early stage Alzheimer’s disease and other dementias. All of the research is being funded by the Alzheimer’s Association’s Part the Cloud to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer’s disease program.

Each of the awardees will receive $1 million over two years to support their research. Since 2012, Part the Cloud has raised more than $29 million to invest in the Alzheimer’s Association research grants. These are “high risk” science projects that need seed funding as the researchers test their ideas and build initial supportive data. The supportive data will allow scientists to seek broader funding from the National Institutes of Health or other sources for larger clinical trials to more definitively test safety and effectiveness.

The grants are funded through the Alzheimer’s Association’s Part the Cloud program. The primary focus is to advance pioneering ideas for early phase human trials – Phase I or Phase 2a proof of concept – targeting brain cell health in Alzheimer’s. The destruction of the brain’s nerve cells causes memory failure, personality changes, problems carrying out daily activities and other symptoms of Alzheimer’s disease dementia.

“Currently, there are no truly effective treatments or preventions for Alzheimer’s disease,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer. “With the aging of the global population, the urgency has never been greater to change that situation and the sooner the better.”

“These Part the Cloud to RESCUE grants encourage discovery and development of a wide range of interventions that might someday be viable treatments for people with or at risk for Alzheimer’s. We are expanding the Alzheimer’s drug pipeline at the front end – Phase 1 and 2 clinical trials – where it is most desperately needed,” Carrillo said. “The research funded by these grants will not only advance possible treatments, but also accelerate our understanding of processes associated with Alzheimer’s and related dementias, as well as other diseases that impact the brain.”

The new grants are awarded to:

Roberta Diaz Brinton, Ph.D., University of Arizona (Tucson, AZ)

This phase 2a study will test whether allopregnanolone, an important hormone in brain function, is able to restore brain cell function in people with Alzheimer’s.

Rafael de la Torre, Pharm.D., Ph.D., Hospital del Mar Medical Research Institute (Barcelona, Spain)

A phase 1 study to test the ability of high dose epigallocatechin gallate (EGCG), an organic compound found in green tea with antioxidant and anti-inflammatory properties known to regulate insulin signals in cells, to reverse cognitive changes in people with early stage Alzheimer’s. The study also includes a lifestyle intervention of diet, exercise and cognitive training that will be tested with the EGCG in a low income, low education community.

Xue Hua, Ph.D., M3 Biotechnology, Inc (Seattle, WA)

This phase 2 proof-of-concept study will evaluate NDX-1017 to determine its potential to treat Alzheimer’s disease and dementia. NDX-1017 is a novel compound focused on regeneration, with a potential to slow, halt or reverse the effects of Alzheimer’s disease, rather than only alleviating symptoms.

Paul A. Newhouse, M.D., Vanderbilt University (Nashville, TN)

A phase 2a study of a new drug, M1-PAM VU319, to improve brain cell communications that could boost memory and attention in people with mild cognitive impairment (MCI). This phase 2a clinical trial will test the drug for the first time in people with MCI.

Stephen M. Strittmatter, M.D., Ph.D., Yale University (New Haven, CT)

Targeting a relatively new approach, this phase 1b study will test a compound, mGluR5 SAM, to target brain cell communication systems for improved brain cell health.

Intent-to-Fund: Raymond Tesi, M.D., INmune Bio (La Jolla, CA)

This phase 1 study will evaluate a new compound, XPRO1595, which aims to reduce inflammation and reverse brain cell death.

Part the Cloud was founded by philanthropist Michaela “Mikey” Hoag after losing her father to younger-onset Alzheimer’s. In partnership with the Alzheimer’s Association, the Part the Cloud movement addresses the critical need to support promising early phase clinical trials to help accelerate the transition of findings from the laboratory into possible therapies.

Part the Cloud is a research funding effort from the Alzheimer’s Association, the world’s leading nonprofit funder of Alzheimer’s and dementia research. The Association is currently investing over $160 million in more than 450 projects in 25 countries. Since 1982, the Association has invested over $435 million to more than 2,900 scientific investigations.

About author

Related Articles